BIOLASE, INC Form 8-K October 30, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	Biolase, Inc.	
	(Exact name of registrant as specified in its chart	er)
Delaware	001-36479	87-0442441
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
4 Cromwell, Irvine, California		92618
ddress of principal executive offices)		(Zip Code)
Registrant s telephone number, inc	cluding area code:	949-361-1200
	Not Applicable	
For	mer name or former address, if changed since last	report


[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company []

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []



On October 30, 2017, Biolase, Inc. issued a press release announcing the record date of 5:00 p.m., Eastern Time on November 8, 2017, for its previously announced rights offering. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

99.1 Press Release of Biolase, Inc., dated October 30, 2017.

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Press Release of Biolase, Inc., dated October 30, 2017.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biolase, Inc.

October 30, 2017 By: \(/s/\) Harold C. Flynn, Jr.

Name: Harold C. Flynn, Jr.

Title: President and Chief Executive Officer

Top of the Form